ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
On November27, 2017, Aldeyra Therapeutics,Inc. (“Aldeyra” or the “Company”) entered into a First Amendment to Lease (the “First Amendment”) with WLC Three VI, L.L.C. (“WLC”) concerning the Company’s corporate headquarters in Lexington, Massachusetts. The First Amendment increases the rentable square footage by 2,427 square feet to 9,351 square feet (the “Phase III Premises”) commencing on or about February1, 2018 (the “Phase III Commencement Date”). The term with respect to the Phase III Premises shall be for a period ending on December31, 2020, or as extended under the Company’s option to extend. In accordance with the terms of the First Amendment, the Company’s base rent shall increase on the Phase III Commencement Date to approximately $219,748.50, subject to annual increases over the term of the lease, and excluding the Company’s pro rata share of certain real property taxes, operating expenses, common area maintenance expenses and allowances for tenant improvements. The First Amendment does not change any other material terms of the lease.
The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by the full text of the First Amendment, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the fiscal period ending December31, 2017.
About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.